ArticleScience advances2022
Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia.
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 23% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Pooled it
- NFATc1 and NFATc2 regulate glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia through modulation of cholesterol biosynthesis and the WNT/β-catenin pathway.Haematologica · 2026Article
- USP7 alterations are associated with a poor survival in pediatric T-cell acute lymphoblastic leukemia.Blood advances · 2025Article
- Design, Synthesis, and Evaluation of Selective Ubiquitin-Specific Protease 11 (USP11) Inhibitors.ACS omega · 2025Article
- USP7 mutations are associated with adverse outcomes in pediatric T cell acute lymphoblastic leukemia and lymphoma.Annals of hematology · 2025Article
- Article
- HNRNPC and m6A RNA methylation control oncogenic transcription and metabolism in T-cell leukemia.Blood · 2025Article
- The USP11/TCEAL1 complex promotes transcription elongation to sustain oncogenic gene expression in neuroblastoma.Genes & development · 2025Article
- MiR-370-3p regulate TLR4/SLC7A11/GPX4 to alleviate the progression of glucocorticoids-induced osteonecrosis of the femoral head by promoting osteogenesis and suppressing ferroptosis.Journal of orthopaedic translation · 2025Article
- The deubiquitinating enzyme USP11 regulates breast cancer progression by stabilizing PGAM5.Breast cancer research : BCR · 2024Article
- Oxyberberine sensitizes liver cancer cells to sorafenib via inhibiting NOTCH1-USP7-c-Myc pathway.Hepatology communications · 2024Article
- Article
- Emerging Epigenetic and Posttranslational Mechanisms Controlling Resistance to Glucocorticoids in Acute Lymphoblastic Leukemia.HemaSphere · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 8 institutions in 5 countries.
Qi JinDepartment of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL, USA.ORCID 0000-0002-4403-2560
Blanca Gutierrez DiazDepartment of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL, USA.ORCID 0000-0001-7588-0274
Tim PietersDepartment of Biomolecular Medicine, Ghent University, Ghent, Belgium.ORCID 0000-0002-2958-0104
Yalu ZhouDepartment of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL, USA.
Sonali NarangDepartment of Pathology, New York University School of Medicine, New York, NY, USA.ORCID 0000-0002-1138-0067
Igor FijalkwoskiDepartment of Biomolecular Medicine, Ghent University, Ghent, Belgium.ORCID 0000-0002-3212-5516
Cristina BorinDepartment of Biomolecular Medicine, Ghent University, Ghent, Belgium.ORCID 0000-0003-0700-6694
Jolien Van LaereDepartment of Biomolecular Medicine, Ghent University, Ghent, Belgium.
Monique PaytonDivision of Experimental Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0001-7257-9099
Byoung-Kyu ChoProteomics Center of Excellence, Northwestern University, Evanston, IL, USA.ORCID 0000-0003-3370-6985
Cuijuan HanDepartment of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL, USA.ORCID 0000-0002-7165-7785
Limin SunDepartment of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL, USA.ORCID 0000-0002-2826-4812
Valentina SerafinOncohematology Laboratory, Department of Women's and Children's Health, University of Padova, Padova, Italy.ORCID 0000-0001-6283-7728
George YacuDepartment of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL, USA.
Wouter Von LoockeDepartment of Pathology, New York University School of Medicine, New York, NY, USA.ORCID 0000-0002-7385-0546
Giuseppe BassoOncohematology Laboratory, Department of Women's and Children's Health, University of Padova, Padova, Italy.
Giulia VeltriOncohematology Laboratory, Department of Women's and Children's Health, University of Padova, Padova, Italy.ORCID 0000-0002-6550-0212
Ingrid DrevenySchool of Pharmacy, University of Nottingham, Nottingham NG7 2RD, UK.ORCID 0000-0003-2256-642X
Issam Ben-SahraDepartment of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL, USA.ORCID 0000-0001-9333-4162
Young Ah GooDepartment of Biochemistry and Molecular Genetics, Northwestern University, Chicago, IL, USA.
Stephanie L SafgrenDivision of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-5503-7324
Yi-Chien TsaiUniversity Children's Hospital, Division of Pediatric Oncology, University of Zurich, Zurich, Switzerland.
Beat BornhauserUniversity Children's Hospital, Division of Pediatric Oncology, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-2890-3191
Praveen Kumar SuraneniDepartment of Cell and Developmental Biology, Northwestern University, Chicago, IL, USA.
Alexandre Gaspar-MaiaDivision of Experimental Pathology and Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-8528-5575
Irawati KandelaCenter for Developmental Therapeutics, Northwestern University, Evanston, IL, USA.
Pieter Van VlierbergheDepartment of Biomolecular Medicine, Ghent University, Ghent, Belgium.ORCID 0000-0001-9063-7205
John D CrispinoDivision of Experimental Hematology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Aristotelis TsirigosDepartment of Pathology, New York University School of Medicine, New York, NY, USA.ORCID 0000-0002-7512-8477
Panagiotis NtziachristosDepartment of Biomolecular Medicine, Ghent University, Ghent, Belgium.ORCID 0000-0001-6374-8954
Northwestern University · USGhent University Hospital · BENew York University · USUniversity of Padua · ITMayo Clinic · USSt. Jude Children's Research Hospital · USUniversity Children's Hospital Zurich · CHUniversity of Nottingham · GB
Funding
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI ELLEN L. GOODE · 2009 to 2026
$37.0MThe impact of changes in chromatin architecture on cancer phenotypes and tumor progressionP01CA229086 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Jane Amanda Skok · 2019 to 2026
$17.0MTargeting Epigenetic Heterogeneity in Pediatric T cell leukemia: Epi-Clones as Drivers of ChemoresistanceR01CA252239 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aristotelis Tsirigos · 2021 to 2026
$3.7MRemodeling of 3D chromatin in B cell acute leukemia and its impact on clinical outcomeR01CA260028 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI CARROLL, WILLIAM L., LIONNET, TIMOTHEE · 2021 to 2025
$2.2MExploring a new therapeutic approach through targeting epigenetic enzymes in ALLR00CA188293 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI NTZIACHRISTOS, PANAGIOTIS · 2015 to 2017
$747kTherapeutic targeting of demethylation-deubiquitination axis in acute leukemiaR01CA248770 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI NTZIACHRISTOS, PANAGIOTIS · 2020 to 2021
$726kNCI NIH HHS P01 CA229086NCI NIH HHS P30 CA016087NCI NIH HHS P50 CA136393NCI NIH HHS R00 CA188293NCI NIH HHS R01 CA248770NCI NIH HHS R01 CA252239Wellcome Trust
Abstract
Dysregulation of kinase signaling pathways favors tumor cell survival and therapy resistance in cancer. Here, we reveal a posttranslational regulation of kinase signaling and nuclear receptor activity via deubiquitination in T cell acute lymphoblastic leukemia (T-ALL). We observed that the ubiquitin-specific protease 11 (USP11) is highly expressed and associates with poor prognosis in T-ALL.
Indexed as
Precursor Cell Lymphoblastic Leukemia-LymphomaCell Line, TumorGlucocorticoidsHumansLymphocyte Specific Protein Tyrosine Kinase p56(lck)Receptors, GlucocorticoidSignal TransductionThiolester HydrolasesUbiquitin-Specific Peptidase 7GlucocorticoidsLymphocyte Specific Protein Tyrosine Kinase p56(lck)Receptors, GlucocorticoidThiolester HydrolasesUbiquitin-Specific Peptidase 7USP11 protein, humanUSP7 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.